Merrimack Pharmaceuticals Inc

NASDAQ:MACKUnited States

Mar 27, 2024

Show headlines and story abstract

• Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan, from 5:30PM ET on Wednesday Mar 27, 2024 by MT Newswires

  5:30PM ET on Wednesday Mar 27, 2024 by MT Newswires
  Companies Mentioned: MACK, ELEV
  05:30 PM EDT, 03/27/2024 (MT Newswires) -- Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution. The ...

• Merrimack Receives $225 Million Milestone Payment from Ipsen, from 4:30PM ET on Wednesday Mar 27, 2024 by Business Wire

  4:30PM ET on Wednesday Mar 27, 2024 by Business Wire
  Companies Mentioned: MACK

  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.

• Merrimack Receives $225 Million Milestone Payment from Ipsen, from 4:30PM ET on Wednesday Mar 27, 2024 by Dow Jones

  4:30PM ET on Wednesday Mar 27, 2024 by Dow Jones
  Companies Mentioned: MACK
  
  require additional data or information or additional studies; (viii) the planned timing of initiation and completion of future clinical studies, if any, are subject to the ability of each of Ipsen and Elevation Oncology, respectively, to enroll patients, enter into agreements with clinical trial sites and investigators, and overcome technical hurdles and other issues related to the conduct of the trials for which each of them is responsible; (ix) each of Ipsen and Elevation Oncology are subject to the risk that they may not successfully commercialize these development programs; and (x) press releases and other public statements by Ipsen and Elevation Oncology may contain forward-looking statements. Merrimack undertakes no obligation to update or revise any forward-looking statements. Forward-looking statements should not be relied upon as representing Merrimack's views as of any date subsequent to the date hereof. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Merrimack's business in general, see the "Risk Factors" section of Merrimack's Annual Report on Form 10-K filed with the SEC on March 7, 2024, any subsequent quarterly report on Form 10-Q filed by Merrimack and the other reports Merrimack files with the Securities and Exchange Commission.